Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Raptor Pharmaceuticals Corp. Plunged Today

By George Budwell - Sep 14, 2015 at 11:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Raptor Pharmaceuticals' shares cratered after a top clinical candidate missed the mark in a mid-stage study.

What: Raptor Pharmaceuticals (NASDAQ: RPTP), a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company's experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug's clinical program for NASH following these disappointing results. 

So what: Given the lack of therapeutic options for children with this serious liver disease, this particular indication for RP103 was seen as one of Raptor's most promising commercial opportunities. 

Now what: While this clinical setback is no doubt unfortunate for investors and patients alike, it's not the end of the world for Raptor. After all, Raptor's FDA-approved treatment for the management of nephropathic cystinosis, Procysbi, is on track to generate $80 to $90 million in net sales this year, and RP103 is still being evaluated in other rare conditions such as Huntington's disease and various mitochondrial disorders.

The company also exited the second quarter with a relatively decent cash and cash equivalent position of $193 million, giving it some headroom to find additional value drivers going forward. Finally, its recent acquisition of Quinsair, a medicine approved in the EU and in Canada for chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis, should also help provide a revenue lift next year. 

Having said that, Raptor looks, to me, to be fairly valued, on a risk-adjusted basis, following RP103's clinical miss in pediatric NASH. So I personally don't plan on picking up any shares today, but may do so if the stock continues moving lower in these days ahead. 

 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.